Nieuws en video's - INCYTE CORP.

Incyte (Nasdaq:INCY) a dévoilé aujourd'hui les résultats de son programme d'études cliniques pivots de Phase 3 TRuE-PN (études TRuE-PN1 et TRuE-PN2) évaluant l'innocuité et l'efficacité du ruxolitinib en crème 1,5 % (Opzelura ® ), un inhibiteur topique de JAK1/2 en administration biquotidienne chez des patients adultes (≥ 18 ans) souffrant de prurigo nodulaire (PN). Les données positives de l'étude TRuE-PN1 ont fait l'objet aujourd'hui d'une présentation orale d'informations les...

Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura ® ), a topical JAK1/2 inhibitor, in adult patients (≥18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented as a late-breaking oral presentation (Session: S028 – Late-Breaking Research: Session 1) today at the 2025 American Academy of Dermatology...

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 13,351 shares of the Company’s common stock to 16 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of March 3, 2025, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the...

Incyte (Nasdaq : INCY) annonce aujourd'hui que de multiples résumés présentant de nouvelles données de son portefeuille de dermatologie seront présentés lors du congrès annuel 2025 de l'Académie américaine de dermatologie (AAD), qui se tiendra du 7 au 11 mars 2025 à Orlando. « Nous sommes ravis de partager de nouvelles données pour la crème à base de ruxolitinib (Opzelura ® ) dans de multiples indications, y compris le prurigo nodulaire et l'axatilimab (Niktimvo™) chez les...

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando. "We look forward to sharing new data for ruxolitinib cream (Opzelura ® ) across multiple indications, including prurigo nodularis, and axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) at this...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45 th Annual Health Care Conference on Monday, March 3, 2025 at 11:10 am (EST) Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 9:20 am (EST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve...

Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided full year 2025 financial guidance. "2024 was an important year for Incyte, with a 15% increase in total revenues, driven by strong growth from both Jakafi and Opzelura, as well as significant progress across our R&D pipeline," said Hervé Hoppenot, Chief Executive Officer, Incyte. "Looking ahead to 2025, we anticipate a year of continued strong revenue growth and...

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 16,301 shares of the Company’s common stock to 24 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of February 3, 2025, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with...

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Monday, February 10, 2025. The schedule for the press release and conference call/webcast is as follows: • Q4 & YE 2024 Press Release: February 10, 2025 at 7:00 a.m. ET • Q4 & YE 2024 Conference Call: February 10, 2025 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 •...

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes PR Newswire WILMINGTON, Del. and WALTHAM, Mass., Jan. 15, 2025 – U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in...

Incyte (Nasdaq:INCY) will provide an update on commercial growth, clinical progress and significant 2025 catalysts during a presentation today at 10:30 a.m. PT at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. “With significant advancements being made across our portfolio, 2025 will be a transformational year not only for Incyte, but also for the patients we serve,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “We have several novel medicines in development...

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 9,502 shares of the Company’s common stock to 14 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of January 2, 2025, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the...

Incyte Corporation (Nasdaq: INCY) announced today that it granted equity inducement awards to Mohamed Issa, the Company’s new Executive Vice President, Head of U.S. Oncology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). As an inducement material...

Incyte (Nasdaq: INCY) announced today that it will present at the 43 rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and...

Incyte (Nasdaq:INCY) a annoncé aujourd'hui des résultats supplémentaires de l'essai pivot de phase 3 inMIND évaluant le traitement par tafasitamab (Monjuvi ® ), un anticorps monoclonal humanisé cytolytique ciblant le CD19 dont le Fc est modifié, en association avec le lénalidomide et le rituximab comparé au placebo plus lénalidomide et rituximab chez les patients atteints de lymphome folliculaire (LF) récidivant ou réfractaire. Ces données sont présentées aujourd'hui lors de la...

Incyte (Nasdaq:INCY) today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab (Monjuvi ® ), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL). These data are featured today in the Late-breaking Session (LBA-1) at the 2024 American Society of Hematology (ASH)...

Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-304 trial of retifanlimab (Zynyz ® ), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy for the treatment of adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer (NSCLC) not harboring a driver mutation. These data were featured today in a mini oral presentation at the European Society for Medical Oncology...

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 7,259 shares of the Company’s common stock to 15 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of December 2, 2024, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the...

Incyte (Nasdaq:INCY) announced today that it will now present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of...

Incyte (Nasdaq : INCY) a annoncé aujourd'hui que la société présenterait de nouvelles données issues de l'ensemble de son portefeuille d'oncologie à l'occasion de la réunion annuelle de l'American Society of Hematology (ASH) qui se tiendra en 2024 à San Diego. « Ces données sont le reflet de notre approche innovante, qui consiste à identifier de nouveaux traitements, les meilleurs de leur catégorie, adaptés aux patients atteints de différents cancers », a indiqué le Dr Pablo J....